Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of TV-1106 (Albutropin) in adults with growth hormone deficiency not currently on rhGH
2014-003796-32Phase 3Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Mar 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in growth hormone deficiency (GHD) comparing TV-1106 (Albutropin) with Placebo (2 arms). Primary endpoint: Primary endpoint: change in body fat composition after 6 months. Started Mar 2015; status: terminated.
02
Drugs
albusomatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2014-003796-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003796-32.